ArticleDiabetes technology & therapeutics2023
Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE.
Article in Diabetes technology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.Diabetes, obesity & metabolism · 2025Trial
- Interpretation of the ambulatory glucose profile in diabetes: practical application in community pharmacy.Farmaceuticos comunitarios · 2026Review
- Impact of User Responses to Smart MDI Notifications: Insights From a Longitudinal Real-World Study of 2604 Smart MDI System Users.Diabetes, obesity & metabolism · 2026Article
- Time in Range and Adverse Outcomes in Type 2 Diabetes: A Quantitative Synthesis.Journal of clinical medicine · 2026Review
- Disordered Eating Behaviors in Children and Adolescents with Type 1 Diabetes: Age-Specific Challenges and Management Insights.Children (Basel, Switzerland) · 2026Review
- Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study.Acta diabetologica · 2025Article
- Role of automated insulin delivery in managing insulin-treated outpatients with type 2 diabetes: A systematic review and meta-analysis.World journal of diabetes · 2025Article
- Time in target range for systolic blood pressure and glucose with cardiovascular disease and all-cause mortality risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Assessing the predictive value of time-in-range level for the risk of postoperative infection in patients with type 2 diabetes: a cohort study.Frontiers in endocrinology · 2025Article
- Observational
- Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-in-range in target.World journal of diabetes · 2024Article
- Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications.Acta diabetologica · 2024Review
- Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.Diabetes technology & therapeutics · 2024Article
- The optimal blood glucose is significantly associated with lower mortality in critically ill patients with cardiogenic shock: an analysis revealed with time series blood glucose records.European journal of medical research · 2024Observational
- Derived Time in Range and Other Metrics of Poor Glycemic Control Associated With Adverse Hospital Outcomes in Patients With Diabetes Mellitus Admitted to Non-ICU Wards at a Tertiary-Level Hospital in Colombia: A Cross-Sectional Study.Journal of diabetes research · 2024Article
- Roadmap to the Effective Use of Continuous Glucose Monitoring: Innovation, Investigation, and Implementation.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Time spent in glycemic target range (time in range [TIR]; plasma glucose 70-180 mg/dL [3.9-10.0 mmol/L]) as a surrogate endpoint for long-term diabetes-related outcomes requires validation. This post hoc analysis investigated the association between TIR, derived from 8-point glucose profiles (derived TIR [dTIR]) at 12 months, and time to cardiovascular or severe hypoglycemic episodes in people with type 2 diabetes in the DEVOTE trial. At 12 months, dTIR was significantly negatively associated with time to first major adverse cardiovascular event (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.